Avian influenza represents one of the greatest concerns for public health that has emerged in recent times. Highly pathogenic avian influenza viruses belonging to the H5N1 subtype are endemic in Asia and are spreading in Europe and Africa. Vaccination is now considered a tool to support eradication efforts, provided it is appropriately managed. This study was carried out to establish the degree of clinical protection and reduction of viral shedding induced by a high-specification, commercially available avian influenza vaccine of a different lineage and containing a strain with a heterologous neuraminidase (H5N9 subtype) to the challenge virus isolate A/chicken/Yamaguchi/7/2004 (H5N1 subtype).
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 51 • No. s1